Elicio Therapeutics, Inc.
ELTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.50 | 0.12 | 0.07 | 0.06 |
| FCF Yield | -6.07% | -7.22% | -12.68% | -14.12% |
| EV / EBITDA | -20.80 | -11.57 | -6.25 | -5.25 |
| Quality | ||||
| ROIC | -35.36% | -46.92% | -57.77% | -76.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.10 | 0.85 | 0.90 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -23.87% | 11.55% | -15.13% | -20.83% |
| Safety | ||||
| Net Debt / EBITDA | 1.90 | 0.71 | 1.17 | -0.63 |
| Interest Coverage | 18.88 | -52.02 | -61.00 | -57.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,237.90 | -1,306.94 | -160.24 |